000661 长春高新
已收盘 09-30 15:00:00
资讯
新帖
简况
长春高新（000661）披露向2026年限制性股票激励计划激励对象授予预留限制性股票公告，9月30日股价上涨1.81%
证券之星 · 09-30 17:35
长春高新（000661）披露向2026年限制性股票激励计划激励对象授予预留限制性股票公告，9月30日股价上涨1.81%
长春高新：第十一届董事会第二十二次会议决议公告
同花顺 · 09-29 21:23
长春高新：第十一届董事会第二十二次会议决议公告
长春高新（000661）披露子公司注射用GenSci136境内生产药品注册临床试验申请获得批准的公告，9月28日股价下跌0.49%
证券之星 · 09-28 22:19
长春高新（000661）披露子公司注射用GenSci136境内生产药品注册临床试验申请获得批准的公告，9月28日股价下跌0.49%
长春高新最新公告：子公司伏欣奇拜单抗注射液临床试验申请获受理
证券之星 · 09-28 18:11
长春高新最新公告：子公司伏欣奇拜单抗注射液临床试验申请获受理
长春高新：公司以AI技术创新为企业战略跃迁的核心驱动力
证券之星 · 09-24
长春高新：公司以AI技术创新为企业战略跃迁的核心驱动力
长春高新：2026年半年度报告披露AI技术应用及在研管线进展
证券之星 · 09-24
长春高新：2026年半年度报告披露AI技术应用及在研管线进展
长春高新：公司经营层正在围绕既定战略目标全力推进各项业务开展
证券之星 · 09-24
长春高新：公司经营层正在围绕既定战略目标全力推进各项业务开展
长春高新：股权激励考核指标兼顾挑战性与可行性
证券之星 · 09-24
长春高新：股权激励考核指标兼顾挑战性与可行性
长春高新：销售费用主要用于销售人员薪酬及差旅、合规学术推广、医患科普、医院准入、渠道建设及新品市场培育
证券之星 · 09-24
长春高新：销售费用主要用于销售人员薪酬及差旅、合规学术推广、医患科普、医院准入、渠道建设及新品市场培育
长春高新（000661）披露子公司RSV单抗组合制剂临床试验申请获受理，9月22日股价下跌0.72%
证券之星 · 09-22
长春高新（000661）披露子公司RSV单抗组合制剂临床试验申请获受理，9月22日股价下跌0.72%
长春高新：公司以经营业绩为市值管理根本
证券之星 · 09-22
长春高新：公司以经营业绩为市值管理根本
长春高新：回购股份用于股权激励
证券之星 · 09-21
长春高新：回购股份用于股权激励
长春高新：销售费用主要用于合规市场推广、渠道覆盖、职工薪酬及差旅等
证券之星 · 09-21
长春高新：销售费用主要用于合规市场推广、渠道覆盖、职工薪酬及差旅等
长效水针垄断终结，长春高新利润神话破灭！
市场资讯 · 09-14
长效水针垄断终结，长春高新利润神话破灭！
长春高新（000661）披露2026年限制性股票激励计划首次授予登记完成公告，9月14日股价上涨1.12%
证券之星 · 09-14
长春高新（000661）披露2026年限制性股票激励计划首次授予登记完成公告，9月14日股价上涨1.12%
长春高新：公司地产子公司尚有部分房屋未出售
证券之星 · 09-11
长春高新：公司地产子公司尚有部分房屋未出售
股市必读：长春高新（000661）9月4日董秘有最新回复
证券之星 · 09-07
股市必读：长春高新（000661）9月4日董秘有最新回复
长春高新子公司GenSci133注射液获批临床 拟用于治疗骨质疏松症
同花顺 · 09-04
长春高新子公司GenSci133注射液获批临床 拟用于治疗骨质疏松症
长春高新：子公司GenSci133注射液临床试验申请获批准
格隆汇 · 09-04
长春高新：子公司GenSci133注射液临床试验申请获批准
长春高新：截止2026年6月30日商誉相关期末余额为7556万元
证券之星 · 09-04
长春高新：截止2026年6月30日商誉相关期末余额为7556万元
加载更多
公司概况
公司名称：
长春高新技术产业(集团)股份有限公司
所属行业：
医药制造业
上市日期：
1996-12-18
主营业务：
长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售。公司的主要产品是生长激素系列产品、促卵泡激素系列、金蓓欣（伏欣奇拜单抗）、美适亚（醋酸甲地孕酮）、安脱达（屋尘螨变应原制剂）等。
发行价格：
8.80
{"stockData":{"symbol":"000661","market":"SZ","secType":"STK","nameCN":"长春高新","latestPrice":71.83,"timestamp":1790751789000,"preClose":70.55,"halted":0,"volume":5187910,"delay":0,"changeRate":0.0181,"floatShares":395000000,"shares":408000000,"eps":-0.8643,"marketStatus":"已收盘","change":1.28,"latestTime":"09-30 15:00:00","open":70.56,"high":72.56,"low":70.21,"amount":373000000,"amplitude":0.0333,"askPrice":71.84,"askSize":3,"bidPrice":71.83,"bidSize":119,"shortable":0,"etf":0,"ttmEps":-0.8643,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791423000000},"marketStatusCode":5,"adr":0,"adjPreClose":70.55,"symbolType":"stock","openAndCloseTimeList":[[1790731800000,1790739000000],[1790744400000,1790751600000]],"highLimit":77.61,"lowLimit":63.5,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":407937529,"isCdr":false,"pbRate":1.28,"roa":"--","roe":"2.14%","epsLYR":0.39,"committee":0.765408,"marketValue":29302000000,"turnoverRate":0.0131,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-10-08。","floatMarketCap":28357000000},"requestUrl":"/m/hq/s/000661/","defaultTab":"news","newsList":[{"id":"2671327096","title":"长春高新（000661）披露向2026年限制性股票激励计划激励对象授予预留限制性股票公告，9月30日股价上涨1.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671327096","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671327096?lang=zh_cn&edition=full","pubTime":"2026-09-30 17:35","pubTimestamp":1790760924,"startTime":"0","endTime":"0","summary":"截至2026年9月30日收盘，长春高新报收于71.83元，较前一交易日上涨1.81%，最新总市值为293.02亿元。该股当日开盘70.56元，最高72.56元，最低70.21元，成交额达3.73亿元，换手率为1.31%。长春高新近日披露《关于向公司2026年限制性股票激励计划激励对象授予预留限制性股票的公告》。股票来源为公司从二级市场回购的A股股票，激励对象为控股子公司金赛药业核心管理、技术和业务骨干。本次授予满足激励计划规定的条件，公司及激励对象均未发生不得授予的情形。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000028077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0057","BK0188","BK0239","BK0075","BK0046","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671217192","title":"长春高新：第十一届董事会第二十二次会议决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2671217192","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671217192?lang=zh_cn&edition=full","pubTime":"2026-09-29 21:23","pubTimestamp":1790688180,"startTime":"0","endTime":"0","summary":" 证券日报网讯 9月29日，长春高新发布公告称，公司于2026年9月29日召开第十一届董事会第二十二次会议，审议通过《关于向公司2026年限制性股票激励计划激励对象 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260929/c680379477.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260929/c680379477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0028","BK0046","BK0188","BK0057","BK0239","BK0075","000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670253064","title":"长春高新（000661）披露子公司注射用GenSci136境内生产药品注册临床试验申请获得批准的公告，9月28日股价下跌0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2670253064","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670253064?lang=zh_cn&edition=full","pubTime":"2026-09-28 22:19","pubTimestamp":1790605156,"startTime":"0","endTime":"0","summary":"截至2026年9月28日收盘，长春高新报收于70.5元，较前一交易日下跌0.49%，最新总市值为287.6亿元。近日，长春高新技术产业（集团）股份有限公司子公司长春金赛药业有限责任公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，其注射用GenSci136境内生产药品注册临床试验申请获得批准，拟用于治疗系统性红斑狼疮。该药此前已获准开展针对全身型重症肌无力、免疫球蛋白A肾病等适应症的临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800034964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0057","BK0075","BK0046","BK0188","000661","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670236302","title":"长春高新最新公告：子公司伏欣奇拜单抗注射液临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2670236302","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670236302?lang=zh_cn&edition=full","pubTime":"2026-09-28 18:11","pubTimestamp":1790590261,"startTime":"0","endTime":"0","summary":"长春高新(000661.SZ)公告称，公司子公司金赛药业收到国家药品监督管理局《受理通知书》，伏欣奇拜单抗注射液境内生产药品注册临床试验申请获受理，拟用于治疗结缔组织病相关间质性肺疾病(CTD-ILD)。该药品为全人源抗白介素-1β单抗，目前尚无药物获批用于所有CTD-ILD人群，临床需求较大。此前该药品用于急性痛风性关节炎适应症已获批上市。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800024470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0057","BK0188","BK0028","000661","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669980634","title":"长春高新：公司以AI技术创新为企业战略跃迁的核心驱动力","url":"https://stock-news.laohu8.com/highlight/detail?id=2669980634","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669980634?lang=zh_cn&edition=full","pubTime":"2026-09-24 20:51","pubTimestamp":1790254272,"startTime":"0","endTime":"0","summary":"长春高新回复：您好，公司2026 年半年度报告中有相关披露内容，具体如下：公司以AI技术创新为企业战略跃迁的核心驱动力，紧密围绕市场需求与临床应用价值，系统地将AI技术应用于研发、流程优化及企业级数字平台，以提升效率并支持创新，已在AI药物发现、大模型设计蛋白、临床研究设计等领域取得实质性突破。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400038282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0046","BK0239","BK0057","BK0028","BK0075","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669715498","title":"长春高新：2026年半年度报告披露AI技术应用及在研管线进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2669715498","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669715498?lang=zh_cn&edition=full","pubTime":"2026-09-24 20:48","pubTimestamp":1790254091,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新09月23日在投资者关系平台上答复投资者关心的问题。请问公司所说多措并举稳定市值，除了常规做好经营外，有没有回购注销、加大AI制药管线信息披露这类实质性行动？本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400038155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0046","BK0057","BK0075","BK0239","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669790455","title":"长春高新：公司经营层正在围绕既定战略目标全力推进各项业务开展","url":"https://stock-news.laohu8.com/highlight/detail?id=2669790455","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669790455?lang=zh_cn&edition=full","pubTime":"2026-09-24 11:33","pubTimestamp":1790220799,"startTime":"0","endTime":"0","summary":"投资者关心的市值管理问题一直未得到解决，股价连续6年下跌，利润也在缩水；另公司销售费用居高不下，但利润回报和销售费用严重倒挂的问题，一直未得到解决长春高新回复：您好，公司经营层正在围绕既定战略目标全力推进各项业务开展，努力实现激励计划设定的考核要求；公司 BD 业务围绕既定战略持续推进，如后续有正式合作协议，公司将严格按照法律法规要求及时履行信息披露义务，具体请以公司公告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400016642.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0057","BK0028","BK0188","BK0239","BK0046","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669455726","title":"长春高新：股权激励考核指标兼顾挑战性与可行性","url":"https://stock-news.laohu8.com/highlight/detail?id=2669455726","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669455726?lang=zh_cn&edition=full","pubTime":"2026-09-24 11:33","pubTimestamp":1790220799,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新09月24日在投资者关系平台上答复投资者关心的问题。当前业绩持续走弱的背景下，管理层仍实施股权激励，相关考核指标设置过低。考核门槛设置如此宽松，业绩一年不如一年仍可达成激励条件，如何保障中小股东权益？股权激励使用的是上市公司全体股东的资源，在经营表现持续低迷时实施激励，管理层如何说明该方案的合理性？","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400016641.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","BK0188","BK0046","BK0028","BK0239","000661","BK0057"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669557184","title":"长春高新：销售费用主要用于销售人员薪酬及差旅、合规学术推广、医患科普、医院准入、渠道建设及新品市场培育","url":"https://stock-news.laohu8.com/highlight/detail?id=2669557184","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669557184?lang=zh_cn&edition=full","pubTime":"2026-09-24 11:33","pubTimestamp":1790220797,"startTime":"0","endTime":"0","summary":"核心生长激素已经进医保，本不需要大量推广，公司销售费用远高于安科生物、特宝生物，但是高额销售费用投入，销售额却没有增长。生长激素医保覆盖适应症有限，多数患者自费；作为处方药，仍需持续开展合规学术推广等；同时公司创新产品上市，需要前期市场投入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400016635.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0075","BK0239","BK0028","BK0046","000661","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669812833","title":"长春高新（000661）披露子公司RSV单抗组合制剂临床试验申请获受理，9月22日股价下跌0.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669812833","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669812833?lang=zh_cn&edition=full","pubTime":"2026-09-22 22:20","pubTimestamp":1790086828,"startTime":"0","endTime":"0","summary":"近日，长春高新技术产业（集团）股份有限公司子公司长春百克生物科技股份公司收到国家药品监督管理局下发的重组人源抗呼吸道合胞病毒单克隆抗体注射液组合制剂临床试验申请的《受理通知书》，受理号为CXSL2601038。该产品用于预防新生儿和婴幼儿由RSV引起的下呼吸道感染，具有良好的药效和安全性，可实现单次给药覆盖一个RSV流行季。目前国内已上市4款RSV抗体，均为单价产品，而百克生物申报的产品为鸡尾酒组合制剂，具有更强的中和活性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200041770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0057","BK0075","BK0046","BK0028","BK0239","000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669116411","title":"长春高新：公司以经营业绩为市值管理根本","url":"https://stock-news.laohu8.com/highlight/detail?id=2669116411","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669116411?lang=zh_cn&edition=full","pubTime":"2026-09-22 15:06","pubTimestamp":1790060784,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新09月22日在投资者关系平台上答复投资者关心的问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200020763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000661","BK0075","BK0239","BK0028","BK0046","BK0057"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669651011","title":"长春高新：回购股份用于股权激励","url":"https://stock-news.laohu8.com/highlight/detail?id=2669651011","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669651011?lang=zh_cn&edition=full","pubTime":"2026-09-21 20:48","pubTimestamp":1789994896,"startTime":"0","endTime":"0","summary":"近两三年公司多次实施股份回购，回购股份全部用于股权激励，其中一次回购还使用了金融机构专项贷款资金。在股价持续低迷、业绩承压的背景下，举债回购用于内部激励，广大中小股东难以认同。为何不考虑将回购股份注销，增厚每股权益，维护全体股东的共同利益？公司回购股份用于股权激励，核心目的是绑定核心员工利益，保障长期经营稳定，并非不重视中小股东权益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100030219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0057","BK0188","BK0028","BK0075","000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669351491","title":"长春高新：销售费用主要用于合规市场推广、渠道覆盖、职工薪酬及差旅等","url":"https://stock-news.laohu8.com/highlight/detail?id=2669351491","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669351491?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:06","pubTimestamp":1789952768,"startTime":"0","endTime":"0","summary":"请说明销售费用的明细构成，解释资金去向，消除投资者对于费用合理性的疑虑。医保只是解决少数患者支付问题，无法自动提升医患认知，仍需持续投入推动规范诊疗、加强科普宣传、维护市场，销售费用主要用于合规市场推广、渠道覆盖、职工薪酬及差旅等，因此销售费用没有大幅下降，具体销售费用构成请参见公司定期报告-财务报告-销售费用相关章节，谢谢！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100001764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0046","BK0028","BK0057","BK0075","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667657928","title":"长效水针垄断终结，长春高新利润神话破灭！","url":"https://stock-news.laohu8.com/highlight/detail?id=2667657928","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667657928?lang=zh_cn&edition=full","pubTime":"2026-09-14 18:04","pubTimestamp":1789380240,"startTime":"0","endTime":"0","summary":"此次激励全部给到核心子公司金赛药业骨干，最终合计238人，授予531.5万股，约占本次激励计划公告日公司股本总额的1.3%。如此力度激励的背后，是长春高新已经持续两年多的利润下滑。长效水针垄断格局终结，三大费用逆势大增长效剂型收入占公司生长激素产品的比重一直在提升。与此同时，此前公司长效水针一家独大的市场格局也已终结。除了费用投放力度不同，还有一方面原因是长春高新的生长激素定价更高、利润更丰厚。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-09-14/doc-iniruxuw4014745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0057","BK0075","BK0239","BK0028","BK0046","000661","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667165477","title":"长春高新（000661）披露2026年限制性股票激励计划首次授予登记完成公告，9月14日股价上涨1.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667165477","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667165477?lang=zh_cn&edition=full","pubTime":"2026-09-14 17:37","pubTimestamp":1789378664,"startTime":"0","endTime":"0","summary":"截至2026年9月14日收盘，长春高新报收于72.26元，较前一交易日上涨1.12%，最新总市值为294.78亿元。公告显示，公司已完成2026年限制性股票激励计划首次授予登记，授予日为2026年8月21日，登记完成日为2026年9月11日。本次实际授予限制性股票484.62万股，授予价格38.08元/股，授予对象234人，均为金赛药业核心管理、技术和业务骨干。首次授予的限制性股票分三年解除限售，解除限售比例分别为40%、30%、30%。本次授予不导致公司控制权及股权分布变化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400023278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0057","BK0188","BK0028","BK0075","000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666542189","title":"长春高新：公司地产子公司尚有部分房屋未出售","url":"https://stock-news.laohu8.com/highlight/detail?id=2666542189","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666542189?lang=zh_cn&edition=full","pubTime":"2026-09-11 16:06","pubTimestamp":1789113972,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新(000661)09月11日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司开发的房地产楼盘目前为止房源是否全部售出，还有未出售的房产吗？这部分房产是否纳入了业绩报表。长春高新回复：您好，公司地产子公司尚有部分房屋未出售，具体变化情况请关注定期报告中存货-开发产品、开发成本相关科目，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。相关 ETF责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100033084.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000661","BK0075","BK0239","BK0028","BK0046","BK0057"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665290362","title":"股市必读：长春高新（000661）9月4日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2665290362","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665290362?lang=zh_cn&edition=full","pubTime":"2026-09-07 01:03","pubTimestamp":1788714192,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，长春高新报收于73.74元，下跌0.46%，换手率1.0%，成交量3.99万手，成交额2.96亿元。董秘： 您好，根据公司2026年半年度报告，截止2026年6月30日商誉相关期末余额为7556万元，整体金额较少，同时公司根据会计准则等要求会持续关注商誉减值等情况，谢谢！当日关注点交易信息汇总：9月4日主力资金净流出588.87万元，占总成交额1.99%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700000505.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","BK0239","000661","BK0046","BK0057","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664332229","title":"长春高新子公司GenSci133注射液获批临床 拟用于治疗骨质疏松症","url":"https://stock-news.laohu8.com/highlight/detail?id=2664332229","media":"同花顺","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664332229?lang=zh_cn&edition=full","pubTime":"2026-09-04 21:23","pubTimestamp":1788528180,"startTime":"0","endTime":"0","summary":"上证报中国证券网讯(记者田甜)长春高新9月4日晚发布公告称，公司控股子公司金赛药业收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，其自主研发的GenSci133注射液境内生产药 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260904/c679621278.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260904/c679621278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0028","000661","BK0075","BK0046","BK0188","BK0239","BK0057"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664387742","title":"长春高新：子公司GenSci133注射液临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664387742","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664387742?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:11","pubTimestamp":1788509503,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0075","BK0028","000661","BK0057","BK0046","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664387143","title":"长春高新：截止2026年6月30日商誉相关期末余额为7556万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664387143","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664387143?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:06","pubTimestamp":1788509182,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新(000661)09月04日在投资者关系平台上答复投资者关心的问题。投资者提问：许多投资者担心公司商誉问题，请问公司是否考虑对商誉减值损失进行一次性计提，以出清市场风险？长春高新回复：您好，根据公司2026年半年度报告，截止2026年6月30日商誉相关期末余额为7556万元，整体金额较少，同时公司根据会计准则等要求会持续关注商誉减值等情况，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400026365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000661","BK0075","BK0188","BK0028","BK0057","BK0046"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1790824875159,"stockEarnings":[{"period":"1week","weight":-0.0194},{"period":"1month","weight":-0.0187},{"period":"3month","weight":0.0394},{"period":"6month","weight":-0.1501},{"period":"1year","weight":-0.4464},{"period":"ytd","weight":-0.2223}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0362},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0098},{"period":"1year","weight":-0.0105},{"period":"ytd","weight":-0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"长春高新技术产业(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"130136人(较上一季度减少5.79%)","perCapita":"3033股","listingDate":"1996-12-18","address":"吉林省长春市朝阳区高新区海容酒店及海茵广场写字楼B座2708室","registeredCapital":"40793万元","survey":" 长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售。公司的主要产品是生长激素系列产品、促卵泡激素系列、金蓓欣（伏欣奇拜单抗）、美适亚（醋酸甲地孕酮）、安脱达（屋尘螨变应原制剂）等。","listedPrice":8.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"长春高新,000661,长春高新股票,长春高新股票老虎,长春高新股票老虎国际,长春高新行情,长春高新股票行情,长春高新股价,长春高新股市,长春高新股票价格,长春高新股票交易,长春高新股票购买,长春高新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}